Given the association between ERK activation and tipifarnib sensitivity, we focused our attention on the RAS/MAPK pathway and other T-cell leukemia/lymphoma-related pathways, such as TCR, JAK/STAT, NFAT and NFκB, which are known to be involved in T-cell leukemia/lymphoma8,11,13,42. This evidence concerns the gene NFKB1 and T-cell leukemia.